The high-end cellomics market size has grown robustly in recent times, scaling from $2.90 billion in 2024 to $3.15 billion in 2025, marking a compound annual growth rate CAGR of 8.6%. The surge in ...

Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10x Genomics, Inc. (NASDAQ: TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

A groundbreaking study shows that the human hippocampus continues producing new neurons well into late adulthood.

Key Takeaways in this Article The global Artificial Intelligence in Genomics market is valued at USD 785.12 million in 2024 and is projected to reach USD 28,999 million by 2035, growing at a CAGR of ...

Review the current valuation for 10x Genomics Inc Ordinary Shares - Class A (TXG:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

10x Genomics Inc Ordinary Shares - Class A 10x Genomics Inc Ordinary Shares - Class A TXG Stock XNAS Rating as of Jun 26, 2025 Download PDF More Actions ...

Discover real-time 10x Genomics, Inc. Class A Common Stock (TXG) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.